biostudies-literatureUnknown14Cardona AFPrecision oncology is the field that places emphasis on the diagnosis and treatment of tumors that harbor specific genomic alterations susceptible to inhibition or modulation. Although most alterations are only present in a minority of patients, a substantial effect on survival can be observed in this subgroup. Mass genome sequencing has led to the identification of a specific driver in the translocations of the tropomyosin receptor kinase family (NTRK) in a subset of rare tumors both in children and in adults, and to the development and investigation of Larotrectinib. This medication was granted approval by the US Food and Drug Administration for NTRK-positive tumors, regardless of histology or age group, as such, larotrectinib was the first in its kind to be approved under the premise thTherapeutic advances in respiratory disease1753466620938553https://www.ebi.ac.uk/biostudies/studies/S-EPMC7350048biostudies-literaturePrecision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries.PMC7350048Ricaurte LRuiz-Patino ARaez LZatarain-Barron ZLArrieta ORojas LMolina-Vila MAZamudio-Molano NBarron FAlvarez MPPRolfo CRosell RCardona AFSotelo CKarachaliou NfalsePrecision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries.Precision oncology is the field that places emphasis on the diagnosis and treatment of tumors that harbor specific genomic alterations susceptible to inhibition or modulation. Although most alterations are only present in a minority of patients, a substantial effect on survival can be observed in this subgroup. Mass genome sequencing has led to the identification of a specific driver in the translocations of the tropomyosin receptor kinase family (NTRK) in a subset of rare tumors both in children and in adults, and to the development and investigation of Larotrectinib. This medication was granted approval by the US Food and Drug Administration for NTRK-positive tumors, regardless of histology or age group, as such, larotrectinib was the first in its kind to be approved under the premise th2020-01-01T00:00:00Z2020 Jan-Dec2026-04-30T03:59:13.983Z2025-06-01T00:11:01.113ZS-EPMC73500483264355310.1177/1753466620938553